In summary, the IKK2 inhibitor TPCA-1 can be slowly released into the posterior segment of the eye from microparticle carriers injected into the retrobulbar space and prevent laser-induced CNV formation, which indicates its potential for treatment of wet AMD and other retinal vascular disorders using this inhibitor. The gene discussed is IKBKB; the disease is wet macular degeneration.